Skip to main content

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

Written by Customer Service on . Posted in Public Companies.

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its participation as an exhibitor at the 15th Annual SCOPE Summit for Clinical Ops Executive (the “SCOPE Summit”) being held February 11-14, 2024 in Orlando, FL. OneMedNet’s Founder and Chief Medical Officer Jeffrey Yu, President Aaron Green, and senior team members, will be on-site to discuss OneMedNet’s iRWDTM solution at the SCOPE Summit’s Real World Evidence track, available at Booth 228.

The 2024 SCOPE Summit will feature two Real World Evidence tracks that highlight the critical importance and innovative science and technology of this specialized data: Accessing and Generating RWD and Leveraging RWD for Clinical Research and Observational Research. OneMedNet continues to expand its network of healthcare systems and providers while also broadening the life sciences market’s accessibility to its specialized RWD, engineered with proprietary Artificial Intelligence (AI) tools, through mainstream online data marketplaces. To learn more about OneMedNet and its Real World Data Solution, please visit www.onemednet.com.

The annual SCOPE Summit is the industry’s most impactful conference exclusively focused on connecting clinical trial operations executives who are actively seeking new technology to improve the experience for patients, sites, and study teams. Now more than ever, the important work of the clinical research community requires collaboration and innovation. In its 15th year of fostering these goals, SCOPE Summit’s programming focuses on advances and innovative solutions in all aspects of clinical trial innovation, planning, management, and operations.

About OneMedNet Corporation

OneMedNet was the first company to trademark a RWD offering through its OneMedNet iRWD™ solution that utilizes AI to securely de-identify, search, and curate imaging data for the benefit of its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet integrates AI and other digital technologies into their existing development processes to enhance data anomaly detection, standardization, and quality checking at the pre-processing stage. AI offers OneMedNet’s partners and customers the ability to increase meaningful Real World Evidence output, decrease time to insights, and make the most of the available vast data sources.

The OneMedNet iRWD network consists of more than 200 healthcare systems and providers. Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. For more information, please visit www.onemednet.com.

Investor Contact

Shannon Devine
MZ Group North America
203-741-8811
ONMD@mzgroup.us

SOURCE: ONEMEDNET CORP.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.